# BRAF V600E

> genetic variant

**Wikidata**: [Q21851559](https://www.wikidata.org/wiki/Q21851559)  
**Wikipedia**: [English](https://en.wikipedia.org/wiki/V600E)  
**Source**: https://4ort.xyz/entity/braf-v600e


## References

1. [CIViC database](https://civic.genome.wustl.edu/links/variants/12)
2. [CIViC database](https://civic.genome.wustl.edu//links?idtype=variant&id=12)
3. [ClinGen Allele Registry](http://reg.clinicalgenome.org/redmine/projects/registry/genboree_registry/by_caid?caid=CA123643)
4. [Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma](https://civic.genome.wustl.edu/links/evidence/95)
5. [Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.](https://civic.genome.wustl.edu/links/evidence/6178)
6. [Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma](https://civic.genome.wustl.edu/links/evidence/6938)
7. [Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.](https://civic.genome.wustl.edu/links/evidence/1408)
8. [Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients](https://civic.genome.wustl.edu/links/evidence/1413)
9. [MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.](https://civic.genome.wustl.edu/links/evidence/1589)
10. [Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial](https://civic.genome.wustl.edu/links/evidence/3017)
11. [Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer](https://civic.genome.wustl.edu/links/evidence/99)
12. [First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors](https://civic.genome.wustl.edu/links/evidence/757)
13. [Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study](https://civic.genome.wustl.edu/links/evidence/1398)
14. [Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer](https://civic.genome.wustl.edu/links/evidence/1405)
15. [Improved survival with vemurafenib in melanoma with BRAF V600E mutation](https://civic.genome.wustl.edu/links/evidence/1409)
16. [Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib](https://civic.genome.wustl.edu/links/evidence/1414)
17. [Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia](https://civic.genome.wustl.edu/links/evidence/1579)
18. [Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial](https://civic.genome.wustl.edu/links/evidence/1591)
19. [Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma](https://civic.genome.wustl.edu/links/evidence/1698)
20. [Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma](https://civic.genome.wustl.edu/links/evidence/1699)
21. [Inhibition of Mutated, Activated BRAF in Metastatic Melanoma](https://civic.genome.wustl.edu/links/evidence/1749)
22. [Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma](https://civic.genome.wustl.edu/links/evidence/3750)
23. [Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers](https://civic.genome.wustl.edu/links/evidence/1141)
24. [Combined vemurafenib and cobimetinib in BRAF-mutated melanoma](https://civic.genome.wustl.edu/links/evidence/1421)
25. [BRAF V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF–MEK Combination Therapy](https://civic.genome.wustl.edu/links/evidence/1430)
26. [Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation](https://civic.genome.wustl.edu/links/evidence/1902)
27. [Improved overall survival in melanoma with combined dabrafenib and trametinib](https://civic.genome.wustl.edu/links/evidence/3758)
28. [Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study](https://civic.genome.wustl.edu/links/evidence/5958)
29. [Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study](https://civic.genome.wustl.edu/links/evidence/5959)
30. [Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study](https://civic.genome.wustl.edu/links/evidence/5960)
31. [Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study](https://civic.genome.wustl.edu/links/evidence/5962)
32. [Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer](https://civic.genome.wustl.edu/links/evidence/6123)
33. [Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer](https://civic.genome.wustl.edu/links/evidence/6124)
34. [Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer](https://civic.genome.wustl.edu/links/evidence/89)
35. [Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan](https://civic.genome.wustl.edu/links/evidence/5906)
36. [Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.](https://civic.genome.wustl.edu/links/evidence/1406)
37. [Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib](https://civic.genome.wustl.edu/links/evidence/1410)
38. [Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations](https://civic.genome.wustl.edu/links/evidence/6940)
39. [Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer](https://civic.genome.wustl.edu/links/evidence/98)
40. [Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer](https://civic.genome.wustl.edu/links/evidence/8506)
41. [Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer](https://civic.genome.wustl.edu/links/evidence/8507)
42. [Improved survival with MEK inhibition in BRAF-mutated melanoma](https://civic.genome.wustl.edu/links/evidence/2135)
43. [The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial](https://civic.genome.wustl.edu/links/evidence/3755)
44. [A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.](https://civic.genome.wustl.edu/links/evidence/3757)
45. [Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.](https://civic.genome.wustl.edu/links/evidence/3777)
46. [Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation](https://civic.genome.wustl.edu/links/evidence/3787)
47. [Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study](https://civic.genome.wustl.edu/links/evidence/5961)
48. [Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations](https://civic.genome.wustl.edu/links/evidence/6045)
49. [Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer](https://civic.genome.wustl.edu/links/evidence/6975)
50. [Interaction between cyclic adenosine monophosphate and cyclic gunaosine monophosphate in guinea pig ventricular myocardium](https://civic.genome.wustl.edu/links/evidence/7260)